Erasca Investor Presentation Deck
August 2023, 56 slides
  1. Erasca
  2. Related Decks
  3. Investor Presentation Decks
on a journey to erase cancer | Erasca
disclaimer forward looking statements market data | Erasca
our name is our mission to erase cancer | Erasca
sab includes world leading experts in the ras pathway | Erasca
lives at stake annually with ras pathway alterations of unmet needs are blue oceans with no approved targeted therapies | Erasca
our singular focus is on the ras pathway sha | Erasca
deep modality agnostic ras pathway focused pipeline class solid tumors | Erasca
our pipeline targets every node of the ras pathway a one era | Erasca
clinical development plan generates multiple ways to win for patients | Erasca
clinical stage programs could address unmet needs in up to million patients annually in the us and seacraft lof eras triple eras | Erasca
pan could address unmet needs in approximately patients in the us and total | Erasca
is a potent and selective inhibitor of and with sub potency and most advanced pan in development | Erasca
has been dosed in more than patients to date establishing its safety tolerability and preliminary in multiple indications | Erasca
| Erasca
current approved standard of care post for metastatic melanoma is chemotherapy with and in setting post | Erasca
phase in melanoma bid showed strong anti tumor activity | Erasca
case study partial response with bid in a patient with melanoma | Erasca
phase in melanoma and exhibited durable time on treatment | Erasca
clinical activity of in melanoma at the likely recommended dose was reproducible across phase and phase studies dor a | Erasca
phase in melanoma analysis of who remain on treatment show potential for to demonstrate benefit | Erasca
phase patients continuing on treatment on potential for confirmation of dor and advantage in seacraft | Erasca
demonstrated a favorable manageable safety profile | Erasca
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
could combine synergistically with the rest of our pipeline seth i a eras | Erasca
eras and eras i could address unmet needs in over patients in the us and it i syne | Erasca
we believe eras is the most potent inhibitor in development with a uniquely longer target residence time may allow intervals for | Erasca
scientific rationale triple blockade of and in patients than | Erasca
eras in | Erasca
meaningful activity in supports initial focus on and dose expansion of this patient segment naive a | Erasca
eras was generally well tolerated with primarily grade or observed | Erasca
early clinical data reinforce potential of eras as a backbone to treat patients with cancers including | Erasca
we believe eras is a potential best in class inhibitor that demonstrates high potency and selectivity against | Erasca
eras in triple and negative erass | Erasca
case study single agent eras response year old female with class metastatic endometrial cancer | Erasca
| Erasca
eras could address high unmet need in patients in us and | Erasca
poor activity of legacy in due to minimal activity against specific alterations and poor penetration | Erasca
eras a potent inhibitor with a over fold higher than approved inhibitors was specifically designed to inhibit in | Erasca
eras significantly extends survival at clinically relevant exposures in an amplified and model vehicle treatment days | Erasca
eras shows significant survival benefit in multiple glioma models harboring a variety of alterations | Erasca
eras improves outcomes of of mutant and or amplified across a diverse range tested | Erasca
anticipated key milestones and clinical trial | Erasca
compelling investment thesis | Erasca
thank you | Erasca
potential first in class pan inhibitor | Erasca
is well positioned to advance through a focused development plan that leverages ras pipeline synergies | Erasca
eras potential best in class inhibitor in a field marked by attrition | Erasca
eras blocked the feedback reactivation observed with or other plus inhibitor combinations | Erasca
case study single agent eras response year old female with kras metastatic pancreatic cancer | Erasca
eras phase responses observed in patients with ras and alterations in diverse tumor types with single agent schedule | Erasca
eras swimmer plot demonstrated encouraging duration of treatment | Erasca
likely recommended dose of eras for combinations has been generally well tolerated | Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
eras potential best in class i favorable profile for combination | Erasca
scientific rationale dual inhibition of and in triple and negative head and neck squamous cell carcinoma | Erasca
eras and eras use different target coverage strategies that seek to achieve optimal efficacy and safety dom | Erasca
See More
Erasca
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Melanoma
Inhibitor
Cancer
Solid tumor
Clinical trial
Recent decks by Erasca
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
July 2021
See all presentations by Erasca (4 decks)
Related decks
Alkermes
Investor Day
March 2021
BioNTech
Results
May 2021
BioNTech
Results
August 2020
BioNTech
Results
August 2021
Nuvalent
Investor Presentation
May 2023
Immix Biopharma
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
September 2023
Recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
July 2021
Alkermes
Investor Day
March 2021
BioNTech
Results
May 2021
BioNTech
Results
August 2020
BioNTech
Results
August 2021
Nuvalent
Investor Presentation
May 2023
Immix Biopharma
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
September 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io